Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 18/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 7/20 | 0.36 |
| ▸ | BRD2 | P25440 | 6/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL313955 | 1.00 | BRD4 (0.37) | BRD4CREBBPBRD2FFAR1ERN1 | |
| SCHEMBL2410464 | 0.85 | BRD4 (0.51) | BRD4CREBBPBRD2FFAR1 | |
| SCHEMBL2410469 | 0.85 | BRD4 (0.51) | BRD4CREBBPBRD2FFAR1 | |
| SCHEMBL2412534 | 0.84 | SLC9A3 (0.42) | BRD4CREBBPBRD2ERN1 | |
| SCHEMBL2412532 | 0.84 | SLC9A3 (0.42) | BRD4CREBBPBRD2ERN1 | |
| SCHEMBL315584 | 0.81 | CYP11B1 (0.32) | BRD4 | |
| SCHEMBL315585 | 0.81 | CYP11B1 (0.32) | BRD4 | |
| SCHEMBL315538 | 0.81 | FFAR1 (0.33) | BRD4CREBBPFFAR1ERN1 | |
| SCHEMBL315537 | 0.81 | FFAR1 (0.33) | BRD4CREBBPFFAR1ERN1 | |
| SCHEMBL314591 | 0.80 | MKNK1 (0.38) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093394-B2 | Derivatives of 5-thioxylopyranose and use of same for treatment | LABORATOIRES FOURNIER S.A. (FR) | 2012-01-10 | — | — | US | disclosed |
| EP-2066683-B1 | DERIVATIVES OF 5-THIOXYLOPYRANOSE AND USE OF SAME FOR TREATMENT | FOURNIER LAB SA (FR) | 2010-11-03 | — | — | EP | disclosed |
| US-20090182013-A1 | Derivatives of 5-Thioxylopyranose and Use of Same for Treatment | LABORATOIRES FOURNIER S.A. (FR) | 2009-07-16 | — | — | US | disclosed |
| EP-2066683-A1 | DERIVATIVES OF 5-THIOXYLOPYRANOSE AND USE OF SAME FOR TREATMENT | LABORATOIRES FOURNIER SA (FR) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008037922-A1 | DERIVATIVES OF 5-THIOXYLOPYRANOSE AND USE OF SAME FOR TREATMENT | LABORATOIRES FOURNIER S.A. (FR) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182013-A1 | Derivatives of 5-Thioxylopyranose and Use of Same for Treatment | TPMT, PNPO, PPOX | BRD4 3810/4885CREBBP 4455/4885BRD2 4694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.